RxDoctor Payments Data

Sarah Harvey

Nurse Practitioner · Lynchburg, VANPI 1144672700

Payments from drug & device makers

$1,194in general payments, 2019–2025

Across 39 payments — averaging $30.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$484
  • Medtronic$259
  • Novartis$153
  • Cardiva Medical, Inc.$142
  • Boston Scientific$68
  • Bayer$43
  • plus $46 from 2 others

What the payments were for

  • Food & beverage$1,18099%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,194 in reported general payments places this provider in the 85th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$14,956
Medicare patients
161
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban281$273,170
XareltoRivaroxaban56$58,612
EntrestoSacubitril/Valsartan31$30,215
Repatha SureclickEvolocumab18$19,978
JardianceEmpagliflozin16$12,479
Repatha SyringeEvolocumab13$8,254
Prasugrel Hcl29$2,260
Metoprolol Succinate121$1,800
Atorvastatin Calcium150$1,435
Ezetimibe24$1,017
ClopidogrelClopidogrel Bisulfate114$846
Famotidine73$679
Potassium Chloride21$636
Carvedilol93$611
Torsemide23$559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$153$30,21531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →